[Targeted therapies in colorectal cancer]

Related Experiment Video

Updated: Jun 5, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Marie-Paule Sablin1, Chantal Dreyer, Camélia Colichi

  • 1Service interhospitalier de cancérologie Bichat-Beaujon, Hôpital Beaujon, AP-HP, 92118 Clichy Cedex. marie-paule.sablin@bjn.aphp.fr

La Revue Du Praticien
|January 5, 2011
PubMed

Insights

Targeted therapies, including antiangiogenic drugs and anti-EGFR agents, improve outcomes for colorectal cancer patients when combined with chemotherapy. KRAS gene mutation status helps select patients for anti-EGFR therapy, optimizing treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advances in cancer biology have identified molecular targets crucial for tumorigenesis.
  • Targeted therapies represent a significant evolution in cancer treatment strategies.

Purpose of the Study:

  • To review the role of targeted therapies in advanced colorectal cancer management.
  • To highlight the impact of antiangiogenic and anti-EGFR agents.
  • To discuss the significance of KRAS mutation as a predictive biomarker.

Main Methods:

  • Review of current literature on targeted therapies in colorectal cancer.
  • Analysis of clinical trial data for bevacizumab, cetuximab, and panitumumab.
  • Examination of the role of KRAS mutation testing in patient selection.

Main Results:

  • Antiangiogenic and anti-EGFR therapies (bevacizumab, cetuximab, panitumumab) are well-tolerated and enhance prognosis with conventional chemotherapy.
  • KRAS gene mutations are identified as predictive factors for resistance to anti-EGFR therapy, enabling better patient stratification.
  • Current management of advanced colorectal cancer integrates chemotherapy, targeted agents, and surgery.

Conclusions:

  • Targeted therapies have become integral to advanced colorectal cancer treatment.
  • Personalized medicine approaches, guided by biomarkers like KRAS mutations, are crucial for optimizing patient outcomes.
  • A multidisciplinary strategy is essential for effective management of advanced colorectal cancer.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...